-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
OPKO Health (NASDAQ:OPK) Reaches New 52-Week Low at $1.83
OPKO Health (NASDAQ:OPK) Reaches New 52-Week Low at $1.83
OPKO Health, Inc. (NASDAQ:OPK – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $1.83 and last traded at $1.83, with a volume of 24088 shares changing hands. The stock had previously closed at $1.88.
Analyst Upgrades and Downgrades
Separately, Piper Sandler lowered their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Friday, August 5th.
Get OPKO Health alerts:OPKO Health Trading Down 4.3 %
The company has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.76. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.48 and a beta of 1.75.
OPKO Health (NASDAQ:OPK – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). OPKO Health had a negative return on equity of 7.72% and a negative net margin of 14.18%. The company had revenue of $309.90 million during the quarter, compared to analyst estimates of $326.87 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The firm's revenue for the quarter was down 30.0% compared to the same quarter last year. On average, research analysts expect that OPKO Health, Inc. will post -0.38 EPS for the current year.Insider Buying and Selling
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 50,000 shares of the business's stock in a transaction dated Friday, September 23rd. The stock was bought at an average cost of $1.85 per share, for a total transaction of $92,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 197,706,694 shares in the company, valued at $365,757,383.90. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders purchased 900,000 shares of company stock worth $2,008,000. 40.97% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of OPK. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $29,000. Aigen Investment Management LP bought a new stake in shares of OPKO Health during the second quarter valued at approximately $29,000. Verition Fund Management LLC bought a new stake in shares of OPKO Health during the second quarter valued at approximately $36,000. Humankind Investments LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $37,000. Finally, Laurion Capital Management LP bought a new stake in OPKO Health in the second quarter valued at $38,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.
OPKO Health Company Profile
(Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
See Also
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
OPKO Health, Inc. (NASDAQ:OPK – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $1.83 and last traded at $1.83, with a volume of 24088 shares changing hands. The stock had previously closed at $1.88.
纳斯达克股票代码：OPK-GET Rating)周一的交易中创下52周新低。该股最低交易价格为1.83美元，最新报1.83美元，成交量为24088股。该股此前收盘价为1.88美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, Piper Sandler lowered their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Friday, August 5th.
另外，派珀·桑德勒将OPKO Health的目标价从5.00美元下调至4.00美元，并在8月5日(星期五)的一份研究报告中为该公司设定了“增持”评级。
OPKO Health Trading Down 4.3 %
Opko Health股价下跌4.3%
The company has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.76. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.48 and a beta of 1.75.
该公司的50日移动均线切入位在2.33美元，200日移动均线切入位在2.76美元。该公司的流动比率为2.30，速动比率为1.91，债务权益比率为0.12。该股市值13.9亿美元，市盈率为-6.48，贝塔系数为1.75。
Insider Buying and Selling
内幕买卖
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 50,000 shares of the business's stock in a transaction dated Friday, September 23rd. The stock was bought at an average cost of $1.85 per share, for a total transaction of $92,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 197,706,694 shares in the company, valued at $365,757,383.90. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders purchased 900,000 shares of company stock worth $2,008,000. 40.97% of the stock is currently owned by insiders.
在OPKO Health的其他新闻中，首席执行官Phillip Md et Al Frost在一笔日期为9月23日星期五的交易中购买了50,000股OPKO股票。这只股票的平均价格为每股1.85美元，总成交额为92,500.00美元。收购完成后，首席执行官现在直接拥有该公司197,706,694股，价值365,757,383.90美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过美国证券交易委员会网站。在过去的90天里，内部人士购买了90万股公司股票，价值2,008,000美元。40.97%的股份目前由内部人士持有。
Institutional Inflows and Outflows
机构资金流入和流出
A number of large investors have recently modified their holdings of OPK. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $29,000. Aigen Investment Management LP bought a new stake in shares of OPKO Health during the second quarter valued at approximately $29,000. Verition Fund Management LLC bought a new stake in shares of OPKO Health during the second quarter valued at approximately $36,000. Humankind Investments LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $37,000. Finally, Laurion Capital Management LP bought a new stake in OPKO Health in the second quarter valued at $38,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.
一些大型投资者最近调整了对OPK的持有量。基石咨询有限责任公司在第四季度购买了OPKO Health公司的新股份，价值约2.9万美元。Aigen Investment Management LP在第二季度购买了OPKO Health的新股份，价值约29,000美元。Verition Fund Management LLC在第二季度购买了OPKO Health的新股份，价值约3.6万美元。人类投资有限责任公司在第一季度购买了OPKO Health的新股份，价值约3.7万美元。最后，Laurion Capital Management LP在第二季度购买了OPKO Health的新股份，价值3.8万美元。该公司27.83%的股票目前由机构投资者和对冲基金持有。
OPKO Health Company Profile
Opko Health公司简介
(Get Rating)
(获取评级)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
Opko Health，Inc.是一家医疗保健公司，在美国、爱尔兰、智利、西班牙、以色列、墨西哥和国际上从事诊断和制药业务。该公司的诊断部门经营着BioReference实验室，该实验室为疾病的检测、诊断、评估、监测和治疗提供实验室测试服务，包括深奥测试、分子诊断、解剖病理学、遗传学、妇女健康以及为医生办公室、诊所、医院、雇主和政府单位提供的矫正保健；以及在护理地点提供血液测试结果的新型诊断仪器系统，以及4KScore前列腺癌测试服务。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- 免费获取StockNews.com关于OPKO健康的研究报告(OPK)
- 三只可能在第四季度表现优异的消费类股
- 康卡斯特是廉价的资产财源
- 合成生物学公司Amyris将在2024年实现净收益吗？
- 卡特彼勒能否在下跌的市场中走得更高？
- Dave&Buster‘s能免受高通胀和低支出的影响吗？
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受OPKO健康日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对OPKO Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧